

A peer-reviewed version of this preprint was published in PeerJ on 18 March 2014.

[View the peer-reviewed version](https://doi.org/10.7717/peerj.316) (peerj.com/articles/316), which is the preferred citable publication unless you specifically need to cite this preprint.

Da'dara AA, Bhardwaj R, Ali YBM, Skelly PJ. 2014. Schistosome tegumental ecto-apyrase (SmATPDase1) degrades exogenous pro-inflammatory and pro-thrombotic nucleotides. PeerJ 2:e316 <https://doi.org/10.7717/peerj.316>

Schistosome tegumental ecto-apyrase (SmATPDase1) degrades exogenous pro-inflammatory and pro-thrombotic nucleotides.

Akram A. Da'dara, Rita Bhardwaj, Yasser MB Ali*, Patrick J. Skelly.

Molecular Helminthology Laboratory, Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA, USA

Corresponding author: Patrick Skelly, Molecular Helminthology Laboratory, Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA, USA. Phone: 508-887-4348; Email: Patrick.Skelly@Tufts.edu

*Current address: Genetic Engineering and Biotechnology Research Institute, Sadat City University, Egypt.

ABSTRACT

Schistosomes are parasitic worms that can survive in the hostile environment of the human bloodstream where they appear refractory to both immune elimination and thrombus formation. We hypothesize that parasite migration in the bloodstream can stress the vascular endothelium causing this tissue to release chemicals alerting responsive host cells to the stress. Such chemicals are called damage associated molecular patterns (DAMPs) and among the most potent is the proinflammatory mediator, adenosine triphosphate (ATP). Furthermore, the ATP derivative ADP is a pro-thrombotic molecule that acts as a strong activator of platelets. Schistosomes are reported to possess at their host interactive tegumental surface a series of enzymes that could, like their homologs in mammals, degrade extracellular ATP and ADP. These are alkaline phosphatase (SmAP), phosphodiesterase (SmNPP-5) and ATP diphosphohydrolase (SmATPDase1). In this work we employ RNAi to knock down expression of the genes encoding these enzymes in the intravascular life stages of the parasite. We then compare the abilities of these parasites to degrade exogenously added ATP and ADP. We find that only SmATPDase1-suppressed parasites are significantly impaired in their ability to degrade these nucleotides. Suppression of SmAP or SmNPP-5 does not appreciably affect the worms' ability to catabolize ATP or ADP. These findings are confirmed by the functional characterization of the enzymatically active, full-length recombinant SmATPDase1 expressed in CHO-S cells. The enzyme is a true apyrase; SmATPDase1 degrades ATP and ADP in a cation dependent manner. Optimal activity is seen at alkaline pH. The K_m of SmATPDase1 for ATP is 0.4 ± 0.02 mM and for ADP, 0.252 ± 0.02 mM. The results confirm the role of tegumental SmATPDase1 in the degradation of the exogenous pro-inflammatory and pro-thrombotic nucleotides ATP and ADP by live intravascular stages of the parasite. By degrading host inflammatory signals like ATP, and pro-thrombotic signals like ADP, these parasite enzymes may minimize host immune responses, inhibit blood coagulation and promote schistosome survival.

INTRODUCTION

Schistosomes are intravascular worms, commonly known as blood flukes that cause the debilitating disease schistosomiasis. Over 200 million people are estimated to be infected with these worms globally and more than 600 million live at risk of infection (Vennervald & Dunne 2004). Disease caused by *Schistosoma mansoni* is characterized clinically by abdominal pain, diarrhea, portal hypertension, anemia and chronic hepatic and intestinal fibrosis (Gryseels et al. 2006).

46 Mature male schistosomes are approximately 10 mm long and possess a ventral groove called the
47 gynaecophoric canal in which the longer, cylindrical adult female often resides. In cross section, the
48 male/female pair spans about 1mm. Both sexes possess a pair of suckers (an anterior oral sucker and a
49 ventral sucker) that are used for attachment to the blood vessel lining and to facilitate intravascular
50 movement (Hockley & McLaren 1973). Large tubercles are present on the dorsal surface of male *S.*
51 *mansoni*, posterior to the ventral sucker. Tubercles are studded with prominent, rigid spines composed of
52 actin bundles (Cohen et al. 1982). Female worms possess relatively few spines and their surface, while
53 smoother and lacking large tubercles, is otherwise similar to the pitted and ridged surface of the male (Senft
54 et al. 1961; Silk et al. 1969).

55
56 *S. mansoni* adult worms wander extensively within the complex venous system draining the intestinal tract
57 (Pellegrino & Coelho 1978). Both single and paired worms move constantly along the vessels (Bloch 1980).
58 The relatively large adults enter blood vessels whose diameter is equivalent to their own (Bloch 1980). In
59 addition, the worms can elongate considerably to enter even smaller vessels, such as the mesenteric venules,
60 to lay eggs (Bloch 1980).

61
62 Parasite suckers, tubercles and spines used for migration in the bloodstream can impinge on host vascular
63 endothelia (Smith & von Lichtenberg 1974). In addition the large, mature schistosomes moving through
64 small blood vessels hamper and alter blood flow (Bloch 1980), almost certainly causing sheer stress and
65 restricting local O₂ concentration. All of these conditions, leading to endothelial cell stress, may trigger the
66 release by these cells of endogenous distress signals. These signals, known collectively as damage-
67 associated molecular patterns (DAMPs), indicate tissue damage to the host and can initiate primary immune
68 responses. Extracellular nucleotides such as ATP are known to function as potent DAMPs by acting as
69 endogenous tissue-derived signaling molecules that contribute to inflammation and immunity. Following
70 tissue damage or during inflammation, or when exposed to shear stress, many cells release ATP (Hanley et
71 al. 2004; Lohman et al. 2012). There is a substantial literature demonstrating that extracellular ATP can
72 function as a proinflammatory immunomediator by acting on multiple immunological effector cell types
73 including neutrophils, macrophages, dendritic cells, and lymphocytes (Reviewed in Bours et al. 2006;
74 Hanley et al. 2004; Yegutkin 2008).

75
76 General activation of the immune system following exposure to DAMPs can be controlled by their
77 degradation in a timely manner. For instance, concentrations of ATP in the extracellular compartments of
78 vertebrates are regulated by the following membrane-bound, nucleotide-metabolizing ecto-enzymes:
79 alkaline phosphatase, phosphodiesterase and ATP-diphosphohydrolase (Bours et al. 2006; Burnstock 2006).
80 ATP degradation in this manner helps prevent uncontrolled inflammation and averts collateral cell damage.

81
82 As noted, schistosomes in the vasculature may directly and indirectly stress the endothelium which could
83 lead to the release of the DAMP, ATP (Bhardwaj & Skelly 2009). This would then stimulate inflammatory
84 immune responses in the vicinity of the worms that could debilitate and kill them. However, it has been
85 shown that schistosomes, like their hosts, express a panel of ecto-enzymes that could catabolize ATP. These
86 are alkaline phosphatase (SmAP), phosphodiesterase (SmNPP-5) and ATP-diphosphohydrolase
87 (SmATPDase1) (Bhardwaj & Skelly 2009). We hypothesize that these parasite tegumental enzymes
88 specifically counteract ATP DAMP-mediated inflammatory signaling and limit the host's attempts to focus
89 inflammatory mediators around the worms (Bhardwaj & Skelly 2009). In this manner, these tegumental
90 molecules help impair host immune defenses and promote parasite survival.

92 In addition to contending with host immunity, intravascular schistosomes, which act as obstructions in the
93 blood vessels, also need adaptations to avoid promoting blood coagulation in their vicinity. The
94 ectoenzymes under study here may exert a key regulatory influence on these processes too. Platelets play a
95 central role in blood clotting and ATP can regulate platelet reactivity by way of direct action on platelet
96 purinergic receptors (Mahaut-Smith et al. 2000). In addition, the first step in ATP hydrolysis leads to the
97 generation of ADP and ADP is a major agonist of platelet recruitment and aggregation (Gachet 2006).
98 Furthermore, platelets themselves can damage schistosomes (Joseph et al. 1983). Therefore the catabolism
99 of ATP and ADP via SmAP, SmNPP-5 and/or SmATPDase1 may additionally lead to the inhibition of
100 platelet aggregation and thrombus formation around the worms.

101
102 It has long been known that schistosome tegumental extracts do possess ATP and ADP hydrolyzing activity
103 (Vasconcelos et al. 1993). Electron microscopy analysis identified electron-dense lead phosphate deposits
104 on the outer surface of adult parasites upon hydrolysis of ATP or ADP and the production of inorganic
105 phosphate (Vasconcelos et al. 1996; Vasconcelos et al. 1993). These data suggest that the activity is external
106 to the body of the worm but do not identify the enzyme(s) responsible. One candidate is schistosome
107 alkaline phosphatase (SmAP). The cDNA encoding SmAP was recently cloned and characterized (Bhardwaj
108 & Skelly 2011). SmAP is a ~62 kDa glycosylphosphatidylinositol (GPI) anchored protein that is expressed
109 in the tegument and internal tissues of the adult worms (Bhardwaj & Skelly 2011; Cesari 1974; Dusanic
110 1959; Levi-Schaffer et al. 1984; Morris & Threadgold 1968; Pujol et al. 1990). The protein can be cleaved
111 from cultured schistosomula (Espinoza et al. 1988) and from adult worms (Castro-Borges et al. 2011) by the
112 phosphatidylinositol-cleaving enzyme - phosphatidylinositol-specific phospholipase C. Tegumental
113 proteomic analysis confirms that SmAP is found in the schistosome surface membranes (Braschi et al. 2006;
114 van Balkom et al. 2005) and is available for surface biotinylation (Braschi & Wilson 2006).

115
116 Proteomic analysis of tegument preparations revealed a second potential ATP and ADP hydrolyzing enzyme
117 there, specifically a phosphodiesterase designated SmNPP-5 that could also be biotinylated at the adult
118 parasite surface (Braschi et al. 2006; Braschi & Wilson 2006). SmNPP-5 is a ~53 kDa protein possessing a
119 single C-terminal transmembrane domain that is expressed exclusively in the intra-mammalian life stages
120 (Rofatto et al. 2009). The protein is expressed highly in the adult tegument and exhibits a unique clustered
121 localization pattern in the tegument as revealed by immunoEM analysis (Bhardwaj et al. 2011).

122
123 A third candidate tegumental, ATP- and ADP-cleaving enzyme is the ATP diphosphohydrolase homolog
124 SmATPDase1 (Vasconcelos et al. 1996; Vasconcelos et al. 1993). This ~63kDa protein possesses an N-
125 terminal and a C-terminal transmembrane domain. It was detected in the adult tegument by
126 immunolocalization (DeMarco et al. 2003; Levano-Garcia et al. 2007) and was identified in adult tegument
127 extracts by proteomic analysis (Braschi et al. 2006; van Balkom et al. 2005). Like SmAP and SmNPP-5,
128 SmATPDase1 was also available for surface biotinylation (Braschi & Wilson 2006).

129
130 In this work we set out to determine whether degradation of the proinflammatory DAMP, ATP, as well as
131 its pro-thrombotic derivative ADP could be mediated by any, or all, of these schistosome enzymes (SmAP,
132 SmNPP-5 and SmATPDase1). We aimed to determine if schistosomes, like their hosts, exhibit redundancy
133 with regard to exogenous ATP and ADP breakdown. In this work we employed RNAi to suppress the
134 expression of the genes encoding these enzymes in order to measure the ability of each to cleave ATP and
135 ADP.

MATERIALS AND METHODS

Parasites.

Snails were provided by the Schistosome Research Reagent Resource Center for distribution by BEI Resources, NIAID, NIH: *Schistosoma mansoni*, strain NMRI exposed *Biomphalaria glabrata* snails, strain NMRI, NR-21962. Cercariae were obtained from infected *B. glabrata* and isolated parasite bodies were prepared as described (Skelly et al. 2003). Parasites were cultured in complete DMEM/F12 medium supplemented with 10% heat-inactivated fetal bovine serum, 200 U/ml penicillin and 200 µg/ml streptomycin, 0.2 µM Triiodo-L-thyronine, 1.0 µM serotonin and 8 µg/ml human insulin. Parasites were maintained at 37 °C, in an atmosphere of 5% CO₂. Adult male and female parasites were recovered by perfusion from Swiss Webster mice that were infected with 125 cercariae, 7 weeks previously. Work with animals was approved by the Tufts University IACUC; protocol number: G2012-150.

Treatment of parasites with siRNAs.

Schistosomula and adult worms were treated with synthetic siRNAs targeting SmAP (GenBank accession number EU040139), SmNPP-5 (GenBank accession number EU769293) and SmATPDase1 (GenBank accession number AY323529). An “irrelevant siRNA” was used as a control and its sequence has no identity in the *S. mansoni* genome. The siRNAs were obtained from IDT, Coralville, IA. The siRNAs targeting SmAP, SmNPP-5, and SmATPDase1 are the following: SmAP: 5'-AAGAAATCAGCAGATGAGAGATTTAAT-3', SmNPP-5: 5'-TTGATGGATTTTCGTTATGATTACTTTG-3', SmATPDase1: 5'-GGACUUUAUGGUUGGGUAUCAGUGA-3'. The control, irrelevant siRNA is: 5'-CT TCCTCTCTTTCTCTCCCTTGTGA-3'.

To deliver the siRNAs, parasites (1000 schistosomula or 10-12 adults/group) in 50-100 µl electroporation buffer (BioRad, CA) containing 2.5 -10 µg siRNA, were electroporated in a 4 mm cuvette by applying a square wave with a single 20-ms impulse, at 125 V and at room temperature, as described (Krautz-Peterson et al. 2007; Ndegwa et al. 2007). To suppress SmAP, SmNPP-5 and SmATPDase1 together, 5 µg of SmAP and SmNPP-5 siRNA and 10 µg SmATPDase1 siRNA were used in the case of adults; 2.5 µg of each siRNA was used in the case of schistosomula. In these experiments, an equivalent amount of the irrelevant siRNA was used in the control group. Parasites were transferred to 500-1300 µl complete DMEM/F12 medium after electroporation. After overnight culture, medium was replaced with fresh rich medium (complete DMEM/F12).

Gene expression analysis.

To assess the level of target gene suppression post-siRNA treatment, RNA and protein were isolated from worm lysates using the PARIS kit (Applied Biosystems, CA). Samples were homogenized on ice using an RNase free pestle for ~1 min and the parasite homogenates were split into two halves. One half was used to isolate RNA and the other for protein analysis. RNA was isolated from the parasite homogenate using the PARIS Kit, as per the manufacturer's guidelines. Residual DNA was removed by DNase digestion using a TurboDNA-free kit (Applied Biosystems, TX). cDNA was synthesized using 1 µg RNA, an oligo (dT)₂₀ primer and Superscript III RT (Invitrogen, CA). Gene expression of SmAP, SmNPP-5 and SmATPDase1 was measured by quantitative real time PCR (qRT-PCR), using custom TaqMan gene expression systems from Applied Biosystems, CA. The primers and probes employed in this research are listed in table 1. The procedure, involving total RNA extraction and quantitative real time PCR, has been described (Krautz-Peterson et al. 2007; Ndegwa et al. 2007). Alpha tubulin was used as the endogenous control gene for relative quantification, as described (Krautz-Peterson et al. 2010), employing the $\Delta\Delta C_t$ method (Livak &

183 Schmittgen 2001). Results obtained from parasites treated with irrelevant siRNA were used for calibration.
184 For graphical representation, the $\Delta\Delta C_t$ values were normalized to controls and expressed as a percentage
185 difference.

186 **Anti-SmAP, anti-SmNPP-5 and anti-SmATPDase1 antibody production.**

187 Anti-SmAP and anti-SmNPP-5 antibodies were generated in rabbits using, in each case, a synthetic peptide
188 as immunogen (Bhardwaj et al. 2011; Bhardwaj & Skelly 2011). Anti-SmATPDase1 antibody, generated in
189 mice against recombinant SmATPDase1 protein, was a kind gift from Dr. Sergio Verjovski-Almeida,
190 University of Sao Paulo, Brazil (DeMarco et al. 2003).
191

192 **Western blotting analysis.**

193 To monitor protein levels, parasite samples were first homogenized on ice in ice-cold cell disruption buffer
194 (PARIS Kit) followed by incubation for 30 minutes on ice to yield total parasite lysate. Protein content was
195 measured using the BCA Protein Assay Kit (Pierce, IL) according to the manufacturer's instructions.
196 Soluble protein (5 μ g in 20 μ l SDS-PAGE sample buffer) was subjected to SDS-PAGE under reducing
197 conditions, blotted onto PVDF membrane and blocked using 5 % skim milk in PBS containing 0.1% Tween
198 20 (PBST) for 1 h at room temperature. The membrane was then probed overnight at 4 °C with anti-SmAP
199 (1:400), or anti-SmNPP-5 (1:200) or SmATPDase1 antiserum (1:10). Following 3 washes with PBST and
200 incubation with donkey anti-rabbit IgG conjugated to horse radish peroxidase (HRP) (GE Healthcare, UK),
201 diluted 1:5000, (for SmAP, and SmNPP-5) and goat anti-mouse IgG conjugated to HRP (Invitrogen)
202 diluted 1:2000, (for SmATPDase1) for 1 hour at 37 °C. Protein bands were visualized using ECL Western
203 Blotting Detection Reagents (GE Healthcare) and X-ray film (ISC BioExpress, Belgium). The same
204 membrane was probed three times to detect SmAP, SmNPP-5 and SmATPDase1. For each re-use, the
205 bound antibody was stripped using Restore Western Blot Stripping Buffer from Thermo Scientific (IL, USA)
206 for 4 h at 37 °C and then washed in PBS twice for 30 min each. To monitor protein loading per lane, a
207 duplicate gel was stained with Coomassie Brilliant Blue, to visually ensure roughly equivalent protein
208 loading per sample.
209

210 **Cloning and transient expression of SmATPDase1 in CHO-S cells.**

211 The complete coding region of SmATPDase1 (accession number AY323529) was codon optimized for
212 expression in hamster and mouse cells by Genscript and cloned into pUC57 (Genscript USA Inc.,
213 Piscataway, NJ). Using this DNA, two constructs were generated for protein expression in mammalian cells:
214 1) the full-length open reading frame (illustrated in figure 4A) was excised from the pUC57 plasmid using
215 the restriction enzymes *NheI* and *XhoI*. These enzyme sites were introduced into the sequence during gene
216 synthesis. The excised DNA was then cloned into the pSecTag2A expression plasmid (Invitrogen) that had
217 been previously digested with the same restriction enzymes. 2) The region encoding just the large
218 extracellular region of SmATPDase1 (encompassing amino-acids S⁶⁶-Q⁵⁰⁷ and lacking both transmembrane
219 domains, indicated in figure 4A) was amplified by PCR using AccuPrime High Fidelity Taq DNA
220 polymerase (Invitrogen) and cloned at the *AscI* and *XhoI* sites in frame with the Igk-leader sequence in the
221 pSecTag2A expression plasmid. All cloned DNAs were sequenced to verify successful in-frame cloning.
222

223 CHO-S cells grown in suspension (Invitrogen) were used for transient SmATPDase1 protein expression. The
224 cells were grown in 30 ml of serum-free Free-Style CHO-S expression medium to 1 X 10⁶ cells/ml. Cells
225 were then transfected with 1 μ g plasmid DNA/ml using Free-Style MAX Transfecting agent according to
226 the manufacturer's instructions (Invitrogen). Seventy two hours later, cells were harvested by centrifugation
227 and cells and culture supernatants were analyzed for SmATPDase1 protein expression. Cell lysates were
228

229 prepared by cell sonication (3 times, 30 sec each) on ice in assay buffer (20 mM HEPES buffer, pH 7.4, 1%
230 Triton X-100, 0.135 M NaCl, 5 mM KCl, 1 mM CaCl₂). Lysates were incubated on ice for 1 hr, centrifuged
231 at 4°C for 20 min at maximum speed. Protein concentration in the recovered supernatants was determined
232 using a BCA kit (Pierce).

233 **SmATPDase1 assay.**

234 Both ATPase and ADPase activities of the recombinant protein were assayed in 96-well microtiter plates at
235 37°C for 30-120 min. The standard 200 µl assay buffer contains 20 mM HEPES buffer, pH 7.4, 1% Triton
236 X-100, 0.135 M NaCl, 5 mM KCl, 1 mM CaCl₂, and recombinant SmATPDase1. Reactions were initiated
237 by the addition of ATP or ADP nucleotide solution to a final concentration of 2 mM. At different time
238 points thereafter, 10 µl aliquots were transferred to 190 µl ice-cold water, and stored at -20°C until analyzed.
239 The amount of inorganic phosphate (Pi) released by the enzyme was determine using a Phosphate
240 Colorimetric Assay Kit (BioVision) according to the manufacturer's instructions. Activity was calculated by
241 subtracting the minimal, nonspecific ATP or ADP hydrolysis that was detected in the absence of the
242 enzyme. Nucleotide hydrolysis was linear with time under the assay conditions used and was proportional to
243 the amount of enzyme used. The linear amount of the enzyme was always determined by performing
244 preliminary assays with different amounts of cell lysate (containing 5-50 µg protein). An equivalent amount
245 of lysate from control or mock transfected cells served as control.
246

247 **SmATPDase1 assays using live parasites and CHO-S cells.**

248 ATP and ADP hydrolysis activities of live parasites, or intact CHO-S cells (expressing recombinant
249 SmATPDase1), or mock transfected cells, were determined as described above with slight modifications.
250 Briefly, live parasites, or CHO-S cells, were first washed 3 times in isotonic wash solution (20 mM HEPES
251 buffer, pH 7.4 containing 0.13 M NaCl, 5 mM KCl, 1 mM CaCl₂, 10 mM Glucose). Next, a specific number
252 of parasites or cells were resuspended in 100 µl isotonic wash solution. Reactions were started by the
253 addition of a 100 µl of the same buffer containing ATP or ADP to produce a final concentration of 2 mM.
254 Released inorganic phosphates were measured using the Phosphate Colorimetric Assay Kit (BioVision)
255 according to the manufacturer's instructions.
256

257 **Characterization of recombinant SmATPDase1 (rSmATPDase1).**

258 Enzyme (10 µg rSmATPDase1) activity was measured in buffer containing 20 mM HEPES, pH 7.4, 1%
259 Triton X-100, 0.135 M NaCl and 5 mM KCl. In some cases this buffer was supplemented with either 1mM
260 CaCl₂ or 1mM MgCl₂ or 1mM EDTA plus 1mM EGTA or 1mM CaCl₂ plus 10, 50 or 100 µM thapsigargin.
261 Reaction conditions were as described above (SmATPDase1 assay).
262

263 K_m values for rSmATPDase1 were determined in the standard assay buffer (described earlier) containing
264 different substrate concentrations (0-2.5 mM) of ATP or ADP. K_m values were calculated using
265 computerized nonlinear regression analysis of the data fitted to the Michaelis-Menten equation using
266 Graphpad Prism 4.0.
267

268 The effect of pH on ATP and ADP hydrolysis by rSmATPDase1 was determined in a 200 µl enzyme assay
269 using a wide-range buffer system covering the pH range of 5.5–10.0 (MES, pH 5.5-6.5; MOPS, pH 6.5-7.5;
270 HEPES, pH 7.0-8.0, Tris-HCl, pH 7.5-9.0; Trizma, pH 9.0; Glycine-NaOH, pH 9.0-10). Assay solutions
271 contained 20 mM buffer, 1% Triton X-100, 0.135 M NaCl, 5 mM KCl, 1 mM CaCl₂, and 2 mM ATP or
272 ADP with 10 µg cell lysate. The reaction was carried out for 30-120 min. Aliquots containing released Pi
273 were assayed at different time points using the phosphate colorimetric assay, as above.
274

Data analysis.

For qRT-PCR and Pi release assay data, one way analysis of variance (ANOVA) and Tukey as the post hoc test was used. Other data were analyzed using the Student's *t*-test. In all cases, differences were considered significant when *P* values <0.05.

RESULTS

Cleavage of exogenous nucleotides by schistosomes

Living schistosomes possess the ability to catabolize exogenous nucleotides. When live adult males are incubated in the presence of ATP, ADP or AMP they cleave these molecules resulting in the release of inorganic phosphate (Pi), as shown in figure 1A. Likewise, groups of living schistosomula incubated with ATP, ADP or AMP cleave these nucleotides (figure 1B). In the case of both adults and schistosomula, most Pi is generated with ATP as substrate, least is generated with AMP as a substrate and an intermediate amount from ADP. One model for schistosome catabolism of these metabolites suggests that three different enzymes with overlapping function may be involved. This proposed pathway for catabolism of exogenous ATP, ADP and AMP by intravascular schistosomes is shown in figure 1C.

SmAP, SmNPP-5 and SmATPDase1 gene suppression using RNAi

In order to uncover which of the enzymes is involved in each step of the exogenous nucleotide catabolism pathway shown in figure 1C, the genes encoding these enzymes were first subjected to suppression using RNAi. Suppression was monitored by qRT-PCR 7 days after treatment and results are shown in figure 2A-C. In each case, gene expression is depicted relative to the control group treated with an irrelevant siRNA (set at 100%, grey bars in figure 2). Relative to the control, it is clear that all 3 targeted genes have been well suppressed (*P*<0.05, in each case). Figure 2A illustrates results for SmAP; the group treated with a specific SmAP siRNA exhibits ~90% lower SmAP gene expression relative to the control group. This is the case when the SmAP siRNA is used alone (lane SmAP, figure 2) or in combination with siRNAs also targeting SmNPP-5 and SmATPDase1 (lane marked "all 3", figure 2A). Similarly, from figure 2B it is clear that when SmNPP-5 is targeted with specific SmNPP-5 siRNA, >90% suppression is observed. Again, this is the case both when SmNPP-5 is targeted with SmNPP-5 siRNA alone (lane SmNPP-5, fig 2B) or with siRNAs also targeting SmAP and SmATPDase1 (lane "all 3", fig 2B). Finally, similar results are seen for SmATPDase1 in figure 2C; in this case ~80% suppression is seen when this gene is targeted with SmATPDase1 siRNA either alone (lane SmATPD, fig 2C) or in addition to siRNAs targeting SmAP and SmNPP-5 ("all 3", fig 2C). Gene knockdown was specific; siRNAs targeting SmAP have no significant effect on SmNPP-5 or SmATPDase1 levels compared to control; suppressing SmNPP-5 did not appreciably impact the SmAP or SmATPDase1 genes. In a similar manner, targeting SmATPDase1 led to its specific knockdown without significant impact on the SmAP or SmNPP-5 genes. Suppression was consistently better for SmAP and SmNPP-5 (>90%) versus SmATPDase1 (~80%). Our attempts to suppress the SmATPDase1 gene still further by using greater amounts of siRNA (up to 35 µg), or different siRNAs, were not successful (data not shown).

In order to assess the impact of gene suppression at the protein level, target-specific antibodies were used in western blotting analyses and results are shown in figure 2D. Protein extracts of control and the triply-suppressed parasites (SmAP, SmNPP-5 and SmATPDase1, lane "All 3" in figure 2D) were probed with anti-SmAP, anti-SmNPP-5 or anti-SmATPDase1 antibodies. It is clear that, in all cases, the siRNA treatment resulted in a substantial diminution in protein levels compared to parasites treated either with irrelevant,

control siRNA (figure 2D, control) or with no siRNA (figure 2D, None). This is the case for SmAP (Figure 2D, top row), SmNPP-5 (second row) and SmATPDase1 (third row). The bottom panel in figure 2D shows a fragment of a Coomassie Blue stained polyacrylamide gel, distant from the location of any of the targets, to illustrate that all lanes contained roughly equivalent amounts of parasite protein.

Parasites with each of the surface enzyme genes suppressed (either separately or all together) exhibited no morphological differences compared to controls. This suggests that high levels of expression of these genes are not very important for the worms in culture.

SmATPDase1 alone is responsible for exogenous ATP and ADP degradation.

The ability of suppressed or control parasites in culture to degrade exogenously added ATP (2 mM) was measured over time. The rate of Pi release per parasite in culture is shown in figure 3A. Each control parasite treated with an irrelevant siRNA generates an average of ~67 nmol Pi/hr (Figure 3A, Control). Likewise, control parasites treated with no siRNA (figure 3A, None) as well as parasites whose SmAP gene or SmNPP-5 gene has been suppressed (figure 3A, SmAP and SmNPP-5) all generate a similar amount of Pi. In contrast, parasites whose SmATPDase1 gene has been suppressed (figure 3A, SmATPD, grey bar) are significantly impaired in their ability to cleave exogenous ATP and liberate Pi ($P < 0.05$); only about 50% of the ATPase activity was detected, compared to controls. These data show that SmATPDase, but not SmAP or SmNPP-5, degrades exogenous ATP.

Next, the ability of suppressed or control parasites in culture to degrade exogenously added ADP (2 mM) was measured over time. Again, the amount of Pi released in culture was measured and results are shown in figure 3B. The data for Pi release, when ADP is the substrate, are broadly similar to those obtained when ATP is used. Parasites whose SmATPDase1 gene is suppressed (figure 3B, SmATPD, grey bar) again generate about 50% of the Pi released by those parasites treated with a control, irrelevant siRNA (figure 3B, control, $P < 0.05$). Parasites whose SmNPP-5 gene or SmAP gene were suppressed (figure 3B, SmNPP-5 and SmAP) generate Pi at a rate not significantly different from the control treated group. These data show that, as for ATP, SmATPDase1, not SmAP or SmNPP-5, degrades exogenous ADP.

Characterization of recombinant SmATPDase1 expressed in CHO cells

From the data presented, it is clear that SmATPDase1 is a key enzyme in the catabolic pathway under study. In order to characterize the enzyme further, efforts were made to express the protein in CHO-S cells in two different forms - in full length form (from residue 1 through 544, as illustrated in figure 4A, top panel) and as a secreted form lacking the predicted N-terminal and C-terminal transmembrane (TM) domains (i.e. from residue S⁶⁶ through Q⁵⁰⁷, indicated in figure 4A, bottom panel). Roughly 72h after cell transfection with plasmid constructs expressing the full-length or the secreted form, ATP or ADP was added to CHO cell lysates (containing 10 μ g protein) and Pi release measured over time. Control cells were not transfected with any plasmid. As shown in figure 4B and C, only lysate from cells expressing the full length protein exhibited activity. This was the case following either ATP addition to the assay (figure 4B, grey bar) or following ADP addition to the assay (figure 4C, grey bar). Any secreted protein was inactive; lysate from cells targeted to express the secreted protein displayed activity indistinguishable from that of control cell lysate (black versus white bars, figure 4B and C).

The expectation is that some of the full length, recombinant SmATPDase1 (rSmATPDase) ecto-enzyme will be expressed on the plasma membrane of the transfected CHO cells. To look for activity at the surface of living CHO cells, transfected and control cells were plated at 75×10^3 or 150×10^3 per well and either ATP

367 (inset figure 4B) or ADP (inset, figure 4C) was added in a Pi release assay. It is clear that the living
368 transfected cells (grey bars, figure 4B and C, insets) can cleave both ATP (figure 4B, inset) and ADP (figure
369 4C, inset) to release Pi at substantially greater levels than controls (white bars, figure 4B and C, insets). As
370 expected, in both cases, greater numbers of cells used in the assay (150×10^3 versus 75×10^3 , figure 4B and
371 C, insets) yield proportionally greater Pi release.
372

373 The activity of rSmATPDase1 was measured under different experimental conditions. As demonstrated in
374 figure 5, the catalytic activity exhibited by SmATPDase1 in the CHO cell lysate towards ATP (figure 5A)
375 and ADP (figure 5D) was markedly increased by the addition of 1mM Mg^{++} to the mixture and (for ATP)
376 increased still further by the addition of 1mM Ca^{++} . Chelating these ions from the original lysate with the
377 addition of EDTA and EGTA greatly reduced the activities detected (figure 5A and D). Adding thapsigargin
378 to the lysate (at 10, 50 or 100 μM) had a minor inhibitory effect (~20% at all concentrations tested) on ATP
379 hydrolysis and an even smaller effect (~5%) on ADP hydrolysis. Only results obtained using the highest
380 thapsigargin concentration tested (100 μM) are shown. The K_m of recombinant SmATPDase1 is 0.4 ± 0.02
381 mM for ATP (figure 5B) and 0.252 ± 0.02 mM for ADP (figure 5E). Both ATP and ADP catalytic activities
382 display pH optima in the alkaline range; the ATPase activity is maximal at $pH \geq 8.5$ (figure 5C) and the
383 ADPase activity is maximal at $pH \geq 7.5$ (figure 5F).
384

385 DISCUSSION

386

387 The migration of intravascular schistosomes can stress blood vessel endothelia (Bloch 1980; Smith & von
388 Lichtenberg 1974) likely leading to the release of host molecules, such as ATP, that signal cell damage
389 (Bhardwaj & Skelly 2009). In the extracellular environment, ATP is a potent proinflammatory mediator and
390 its byproduct (ADP) is potently pro-thrombotic. It has been hypothesized that schistosomes have evolved to
391 impede host immunity and thrombus formation by degrading these host signaling molecules using
392 nucleotide metabolizing enzymes expressed on their surface (Bhardwaj & Skelly 2009).
393

394 It has long been known that schistosome tegumental extracts do possess ATP and ADP hydrolyzing
395 capabilities and that living worms can deplete exogenous ATP and ADP (Vasconcelos et al. 1993). Here we
396 confirm that living parasites (both adults and schistosomula) can degrade exogenous ATP, ADP and AMP.
397 In the case of vertebrates, ectoenzymes belonging to three different classes are known to engage in the
398 extracellular ATP degradation pathway (Bours et al. 2006). These are alkaline phosphatase,
399 phosphodiesterase and ATPdiphosphohydrolase. In what appears to be considerable redundancy in
400 vertebrates, enzymes belonging to these three classes can all mediate ATP and ADP breakdown while two
401 of the three can mediate AMP breakdown (Bours et al. 2006). Using this literature as a guide, we
402 hypothesized that the exogenous ATP degradation pathway in schistosomes could similarly be mediated by
403 several known tegumental enzymes belonging to these enzyme classes. These are SmAP, SmNPP-5 and
404 SmATPDase1.
405

406 In this paper, the hypothesis that schistosomes possess equivalent redundancy to vertebrates in their ability
407 to degrade extracellular ATP and ADP was tested. First, RNAi was employed to suppress the expression of
408 all 3 ectoenzyme genes (either alone or in combination). The expression of each gene is robustly and
409 specifically suppressed both when that gene is targeted by itself or with other genes. Suppression at the
410 RNA level is confirmed by quantitative real-time PCR analysis; suppression at the protein level is seen by
411 western blotting analysis.
412

413 When parasites that have had all 3 ectoenzyme genes suppressed were maintained in culture for up to 4
414 weeks they exhibited no morphological differences when compared to controls. This suggests that normal
415 expression of the genes encoding the three ectoenzymes is not essential for worm survival in culture and is
416 in agreement with the hypothesis that these enzymes are primarily important for parasites within the
417 vertebrate host where they act to minimize host purinergic signaling.
418

419 The first step in the pathway under study here is the catabolism of ATP to ADP. In order to decipher which
420 of the three enzymes participate in this step, their genes were suppressed using RNAi. Next, the ability of
421 the SmAP- or SmNPP-5- or SmATPDase-suppressed parasites to degrade ATP (added to the assay buffer)
422 was compared with the ability of controls to degrade ATP. The results are clear - of these 3 gene
423 knockdown conditions, it is only following SmATPDase1 knockdown that parasites exhibit a reduced
424 ability to cleave exogenous ATP, in comparison to controls. The SmAP- and SmNPP-5-suppressed adult
425 parasites were not impacted in their ATP-hydrolyzing ability, which was comparable to the controls. Only
426 the ATP degrading ability of the SmATPDase1-suppressed parasites was significantly reduced. Thus, unlike
427 vertebrates, schistosomes utilize just one ectoenzyme to cleave ATP. There is no redundancy in
428 schistosomes at this step.
429

430 The second step in the pathway involves the cleavage of ADP. A similar experiment to that just described
431 for ATP was undertaken; the ability of SmAP- or SmNPP-5- or SmATPDase-suppressed parasites versus
432 controls to degrade ADP (added to the assay buffer) was compared. It was observed that the SmATPDase-
433 suppressed group alone exhibited a lessened ability to cleave ADP. The SmAP- and SmNPP-5 suppressed
434 parasites had no impairment in ADP cleavage compared to controls. As for ATP cleavage, this second ADP-
435 cleavage step is also non-redundant in schistosomes. SmATPDase, in addition to being an ATPase, is also
436 an ADPase.
437

438 The final step in the pathway is the cleavage of AMP to generate adenosine. In previous work it has been
439 established that SmAP fulfills this function (Bhardwaj & Skelly 2011). Thus the final pathway in
440 schistosomes is simpler than that observed in vertebrates and is illustrated in figure 6. The third enzyme,
441 SmNPP-5 does not participate in this pathway. While its function at the surface of the intravascular worms
442 is not known, SmNPP-5 does fulfill an important role for schistosomes since it has been shown that
443 parasites whose SmNPP-5 gene is suppressed fail to establish a robust infection in mice (Bhardwaj et al.
444 2011).
445

446 To confirm that SmATPDase1 is a true apyrase i.e. it can cleave ATP and ADP to yield AMP and Pi, as
447 suggested by the gene knockdown experiments, a recombinant form of the protein was expressed in CHO-S
448 cells. Attempts were made to generate a soluble form of SmATPDase1 (lacking transmembrane domains but
449 retaining all key enzymatic motifs). While this goal was achieved, the soluble protein was enzymatically
450 inactive, likely due to incorrect post-translational handling. In contrast, a full-length version of
451 SmATPDase1 was generated in CHO-S cells that was active. The retention of the two terminal,
452 transmembrane domains in this full-length recombinant protein seems important for proper folding and may
453 help to maintain the protein in an enzymatically favorable conformation. There is firm evidence from work
454 with ATPDases in other systems that the interaction of the transmembrane domains and their mobility in a
455 lipid bilayer regulate enzyme catalysis (Knowles 2011). For instance, the extracellular domain of the
456 chicken NTPDase8 enzyme has a small fraction of the activity of the full length enzyme (Li et al. 2010). At
457 least some of the full length SmATPDase1 ectoenzyme expressed here is found in the plasma membrane of

458 the CHO-S cells such that live intact cells expressing the protein display both ATP and ADP cleaving
459 capabilities.

460
461 The ability of recombinant SmATPDase1 expressed in CHO-S cells to hydrolyze ATP and ADP was found
462 to be enhanced by the addition of divalent cations to the mixture; adding Ca^{++} or Mg^{++} to the rSmATPDase1
463 preparation greatly increases activity. Adding Mg^{++} or Ca^{++} to schistosome tegument preparations had
464 previously been shown to promote ATPase and ADPase activity (Torres et al. 1998; Vasconcelos et al.
465 1993). As reported here, removing these cations from the rSmATPDase1 preparation by the addition of the
466 chelating agents EDTA plus EGTA effectively shuts down the enzyme. The fact that SmATPDase1 is a
467 calcium-activated plasma membrane-bound enzyme again confirms it as a member of the apyrase family.
468 Earlier substrate competition experiments (ATP versus ADP) involving schistosome tegument extracts, as
469 well as comparative heat inactivation profiles for ATP versus ADP hydrolytic activities using these extracts,
470 led to the hypothesis that a single enzyme in the tegument was responsible for degrading both ATP and
471 ADP (Martins et al. 2000; Vasconcelos et al. 1993). Our work confirms this hypothesis. Furthermore, under
472 physiological conditions the K_m of rSmATPDase1 for ATP is 0.4 ± 0.02 mM and for ADP is 0.252 ± 0.02
473 mM and these values are almost identical to those reported for the ATPase activity and the ADPase activity
474 of adult *S. mansoni* tegumental extracts (0.25mM for ADP and 0.45 mM for ATP, Vasconcelos et al. 1993).
475

476 As discussed, the apyrase activity detected in schistosome tegument membrane preparations has a very
477 similar profile to that described here for rSmATPDase1. One difference is apparent however; the ATPase
478 activity of the tegument preparation (but not its ADPase activity) has been reported to be inhibited by
479 thapsigargin in a dose dependent manner (Martins et al. 2000). Inhibition of ~70% was seen with 100 μM
480 thapsigargin (Martins et al. 2000). This finding was a surprise since thapsigargin is best known as a specific
481 inhibitor of sarco/endoplasmic reticulum Ca^{++} (SERCA) ATPases and not of apyrases (Rogers et al. 1995).
482 Our finding is that there is no dose-dependent inhibitory effect of thapsigargin on rSmATPDase1 activity; at
483 all thapsigargin concentrations tested (10-100 μM) ATPase activity is decreased by ~20% and ADPase
484 activity by ~5%. Our data show that, as for other apyrases, the SmATPDase1 enzyme is not intrinsically
485 inhibitable by thapsigargin in a dose dependent manner. The inhibition reported (Martins et al. 2000) is
486 likely related to the use of tegument preparations rather than recombinant enzyme.
487

488 As shown here, both ATP and ADP cleavage activities of rSmATPDase1 are more pronounced in an
489 alkaline environment. Earlier, the ATPase activity detected in adult schistosome tegumental membrane
490 extracts was reported to be similarly enhanced under alkaline conditions (Cesari et al. 1981). Furthermore,
491 other enzyme activities (alkaline phosphatase and phosphodiesterase) detectable in tegument extracts are
492 likewise greatest at $\text{pH} > 9$ (Cesari et al. 1981). Why the three ectoenzymes SmAP, SmNPP-5 and
493 SmATPDase1, expressed at the host-parasite interface, should all display highest activity under alkaline
494 conditions is unclear. Perhaps schistosomes *in vivo* maintain an alkaline environment immediately around
495 them in which these enzymes optimally act and which has some selective advantage for the worms.
496

497 Our work demonstrates that the three ecto-enzyme genes SmAP, SmNPP-5 and SmATPDase1 can all be
498 specifically and strongly knocked down using target specific siRNAs. It is noteworthy that roughly
499 equivalent suppression is obtained irrespective of whether each gene is targeted alone or together with the
500 other two targets. In other words there is no compromise in suppression efficiency when all three genes are
501 targeted together, demonstrating that the RNAi machinery in schistosomes is not saturated by multiple
502 siRNAs targeting different mRNAs at the same time.
503

504 Just as important for schistosomes as the elimination of potentially damaging host signaling molecules like
505 ATP and ADP by SmATPDase1 may be the generation of adenosine from AMP via SmAP. This is because
506 many of the proinflammatory effects of ATP on immune cells can be suppressed or reversed by adenosine
507 (Reviewed in Bours et al. 2006; Hasko & Cronstein 2004). Extracellular adenosine can impede the
508 chemotactic responses of macrophages and monocytes and can inhibit both their production of pro-
509 inflammatory cytokines as well as macrophage proliferation, phagocytosis and lysosomal enzyme secretion
510 (Bours et al. 2006; Riches et al. 1985). Extracellular adenosine can inhibit the production of reactive
511 nitrogen species and reactive oxygen species by monocytes/macrophages and neutrophils (Bours et al. 2006;
512 Flamand et al. 2000). In addition, adenosine can impede lymphocyte adhesion and attenuate the proliferative
513 and cytotoxic responses of activated T cells (Bours et al. 2006; Hasko & Cronstein 2004).

514
515 On a more mundane level, the adenosine generated by this pathway may be directly taken up by
516 schistosomes as food (Levy & Read 1975b). The ATP catabolic pathway may be used to generate purine
517 derivatives in the vicinity of the worms that can then be easily imported and this function may have
518 particular importance for schistosomes since the parasites are unable to synthesize purines *de novo* (Levy &
519 Read 1975a). The hypotheses that any adenosine generated via this pathway may be taken in by the
520 parasites as food or may act to impede host purinergic signaling are not mutually exclusive.

521
522 Since the 3 ecto-enzymes may make good vaccine candidates, all have been purified from inclusion bodies
523 following their expression as recombinant proteins in *E. coli* (Rofatto et al. 2013). In vaccine trials,
524 immunization with the isolated individual proteins, or with all three proteins combined, did not reduce the
525 worm burden of challenged mice. However, immunization with SmAP alone or with all three proteins
526 together, when combined with subcurative treatment with the drug praziquantel, was able to reduce worm
527 burdens by ~ 40% (Rofatto et al. 2013).

528
529 An ability to cleave ATP and/or ADP in the extracellular environment has been described in several
530 pathogens. For example ecto-ATPase activity has been described in the protozoan parasites *Toxoplasma*
531 *gondii* (Bermudes et al. 1994), *Leishmania amazonensis* (Berredo-Pinho et al. 2001), *Trichomonas vaginalis*
532 (de Jesus et al. 2002) and *Cryptosporidium parvum* (Manque et al. 2012) and in several bacterial pathogens
533 including *Mycobacterium bovis* (Zaborina et al. 1999), *Vibrio cholera* (Punj et al. 2000), *Staphylococcus*
534 *aureus* (Thammavongsa et al. 2009), and *Legionella pneumophila* (Vivian et al. 2010). Similarly, blood-
535 feeding ectoparasites are known to release a repertoire of nucleotide-metabolizing enzymes in their saliva
536 (Andersen et al. 2007; de Araujo et al. 2012). The parasitic nematode *Trichinella spiralis* secretes a panel of
537 nucleotide metabolizing enzymes (Gounaris 2002). Thus a conserved feature of several pathogens, including
538 schistosomes, is an ability to control local ATP and ADP levels, perhaps to thereby inhibit inflammation and
539 thrombosis and protect the pathogens. Identifying chemical inhibitors of SmATPDase1 to negate the
540 worm's ability to degrade exogenous pro-inflammatory and pro-thrombotic nucleotides may offer a novel
541 therapeutic option to treat schistosomiasis.

542 543 **Acknowledgements**

544
545 Infected snails were provided by the Biomedical Research Institute via the NIAID schistosomiasis resource
546 center under NIH-NIAID Contract No. HHSN272201000005I. We thank Dr. Chuck Shoemaker for helpful
547 discussion and Dr. Sergio Verjovski-Almeida, University of Sao Paulo, Brazil for the anti-SmATPDase1
548 antibody.

REFERENCES

- Andersen JF, Hinnebusch BJ, Lucas DA, Conrads TP, Veenstra TD, Pham VM, and Ribeiro JM. 2007. An insight into the sialome of the oriental rat flea, *Xenopsylla cheopis* (Rots). *BMC Genomics* 8:102.
- Bermudes D, Peck KR, Afifi MA, Beckers CJ, and Joiner KA. 1994. Tandemly repeated genes encode nucleoside triphosphate hydrolase isoforms secreted into the parasitophorous vacuole of *Toxoplasma gondii*. *J Biol Chem* 269:29252-29260.
- Berreto-Pinho M, Peres-Sampaio CE, Chrispim PP, Belmont-Firpo R, Lemos AP, Martiny A, Vannier-Santos MA, and Meyer-Fernandes JR. 2001. A Mg-dependent ecto-ATPase in *Leishmania amazonensis* and its possible role in adenosine acquisition and virulence. *Arch Biochem Biophys* 391:16-24.
- Bhardwaj R, Krautz-Peterson G, Da'dara A, Tzipori S, and Skelly PJ. 2011. Tegumental Phosphodiesterase SmNPP-5 Is a Virulence Factor for Schistosomes. *Infection and immunity* 79:4276-4284.
- Bhardwaj R, and Skelly PJ. 2009. Purinergic signaling and immune modulation at the schistosome surface? *Trends Parasitol* 25:256-260.
- Bhardwaj R, and Skelly PJ. 2011. Characterization of schistosome tegumental alkaline phosphatase (SmAP). *PLoS neglected tropical diseases* 5:e1011.
- Bloch EH. 1980. In vivo microscopy of schistosomiasis. II. Migration of *Schistosoma mansoni* in the lungs, liver, and intestine. *Am J Trop Med Hyg* 29:62-70.
- Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, and Dagnelie PC. 2006. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. *Pharmacol Ther* 112:358-404.
- Braschi S, Curwen RS, Ashton PD, Verjovski-Almeida S, and Wilson A. 2006. The tegument surface membranes of the human blood parasite *Schistosoma mansoni*: a proteomic analysis after differential extraction. *Proteomics* 6:1471-1482.
- Braschi S, and Wilson RA. 2006. Proteins exposed at the adult schistosome surface revealed by biotinylation. *Mol Cell Proteomics* 5:347-356.
- Burnstock G. 2006. Pathophysiology and therapeutic potential of purinergic signaling. *Pharmacol Rev* 58:58-86.
- Castro-Borges W, Dowle A, Curwen RS, Thomas-Oates J, and Wilson RA. 2011. Enzymatic shaving of the tegument surface of live schistosomes for proteomic analysis: a rational approach to select vaccine candidates. *PLoS neglected tropical diseases* 5:e993.
- Cesari IM. 1974. *Schistosoma mansoni*: distribution and characteristics of alkaline and acid phosphatase. *Exp Parasitol* 36:405-414.
- Cesari IM, Simpson AJ, and Evans WH. 1981. Properties of a series of tegumental membrane-bound phosphohydrolase activities of *Schistosoma mansoni*. *Biochem J* 198:467-473.
- Cohen C, Reinhardt B, Castellani L, Norton P, and Stirewalt M. 1982. Schistosome surface spines are "crystals" of actin. *J Cell Biol* 95:987-988.
- de Araujo CN, Bussacos AC, Sousa AO, Hecht MM, and Teixeira AR. 2012. Interactome: Smart hematophagous triatomine salivary gland molecules counteract human hemostasis during meal acquisition. *J Proteomics* 75:3829-3841.
- de Jesus JB, de Sa Pinheiro AA, Lopes AH, and Meyer-Fernandes JR. 2002. An ectonucleotide ATP-diphosphohydrolase activity in *Trichomonas vaginalis* stimulated by galactose and its possible role in virulence. *Z Naturforsch C* 57:890-896.

- 594 DeMarco R, Kowaltowski AT, Mortara RA, and Verjovski-Almeida S. 2003. Molecular characterization
595 and immunolocalization of *Schistosoma mansoni* ATP-diphosphohydrolase. *Biochem Biophys Res Commun*
596 307:831-838.
- 597 Dusanic DG. 1959. Histochemical observations of alkaline phosphatase in *Schistosoma mansoni*. *J Infect*
598 *Dis* 105:1-8.
- 599 Espinoza B, Tarrab-Hazdai R, Silman I, and Arnon R. 1988. Acetylcholinesterase in *Schistosoma mansoni*
600 is anchored to the membrane via covalently attached phosphatidylinositol. *Mol Biochem Parasitol* 29:171-
601 179.
- 602 Flamand N, Boudreault S, Picard S, Austin M, Surette ME, Plante H, Krump E, Vallee MJ, Gilbert C,
603 Naccache P et al. . 2000. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene
604 biosynthesis in human neutrophils. *Am J Respir Crit Care Med* 161:S88-94.
- 605 Gachet C. 2006. Regulation of platelet functions by P2 receptors. *Annu Rev Pharmacol Toxicol* 46:277-300.
- 606 Gounaris K. 2002. Nucleotidase cascades are catalyzed by secreted proteins of the parasitic nematode
607 *Trichinella spiralis*. *Infection and immunity* 70:4917-4924.
- 608 Gryseels B, Polman K, Clerinx J, and Kestens L. 2006. Human schistosomiasis. *Lancet* 368:1106-1118.
- 609 Hanley PJ, Musset B, Renigunta V, Limberg SH, Dalpke AH, Sus R, Heeg KM, Preisig-Muller R, and Daut
610 J. 2004. Extracellular ATP induces oscillations of intracellular Ca²⁺ and membrane potential and promotes
611 transcription of IL-6 in macrophages. *Proc Natl Acad Sci U S A* 101:9479-9484.
- 612 Hasko G, and Cronstein BN. 2004. Adenosine: an endogenous regulator of innate immunity. *Trends*
613 *Immunol* 25:33-39.
- 614 Hockley DJ, and McLaren DJ. 1973. *Schistosoma mansoni*: changes in the outer membrane of the tegument
615 during development from cercaria to adult worm. *Int J Parasitol* 3:13-25.
- 616 Joseph M, Auriault C, Capron A, Vorng H, and Viens P. 1983. A new function for platelets: IgE-dependent
617 killing of schistosomes. *Nature* 303:810-812.
- 618 Knowles AF. 2011. The GDA1_CD39 superfamily: NTPDases with diverse functions. *Purinergic Signal*
619 7:21-45.
- 620 Krautz-Peterson G, Radwanska M, Ndegwa D, Shoemaker CB, and Skelly PJ. 2007. Optimizing gene
621 suppression in schistosomes using RNA interference. *Mol Biochem Parasitol* 153:194-202.
- 622 Krautz-Peterson G, Simoes M, Faghiri Z, Ndegwa D, Oliveira G, Shoemaker CB, and Skelly PJ. 2010.
623 Suppressing glucose transporter gene expression in schistosomes impairs parasite feeding and decreases
624 survival in the mammalian host. *PLoS pathogens* 6:e1000932.
- 625 Levano-Garcia J, Mortara RA, Verjovski-Almeida S, and DeMarco R. 2007. Characterization of
626 *Schistosoma mansoni* ATPDase2 gene, a novel apyrase family member. *Biochem Biophys Res Commun*
627 352:384-389.
- 628 Levi-Schaffer F, Tarrab-Hazdai R, Schryer MD, Arnon R, and Smolarsky M. 1984. Isolation and partial
629 characterization of the tegumental outer membrane of schistosomula of *Schistosoma mansoni*. *Mol Biochem*
630 *Parasitol* 13:283-300.
- 631 Levy MG, and Read CP. 1975a. Purine and pyrimidine transport in *Schistosoma mansoni*. *J Parasitol*
632 61:627-632.
- 633 Levy MG, and Read CP. 1975b. Relation of tegumentary phosphohydrolase to purine and pyrimidine
634 transport in *Schistosoma mansoni*. *J Parasitol* 61:648-656.
- 635 Li CS, Lee Y, and Knowles AF. 2010. The stability of chicken nucleoside triphosphate diphosphohydrolase
636 8 requires both of its transmembrane domains. *Biochemistry* 49:134-146.
- 637 Livak KJ, and Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative
638 PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402-408.

639 Lohman AW, Billaud M, and Isakson BE. 2012. Mechanisms of ATP release and signalling in the blood
640 vessel wall. *Cardiovasc Res* 95:269-280.

641 Mahaut-Smith MP, Ennion SJ, Rolf MG, and Evans RJ. 2000. ADP is not an agonist at P2X(1) receptors:
642 evidence for separate receptors stimulated by ATP and ADP on human platelets. *Br J Pharmacol* 131:108-
643 114.

644 Manque PA, Woehlbier U, Lara AM, Tenjo F, Alves JM, and Buck GA. 2012. Identification and
645 characterization of a novel calcium-activated apyrase from *Cryptosporidium* parasites and its potential role
646 in pathogenesis. *PLoS One* 7:e31030.

647 Martins SM, Torres CR, and Ferreira ST. 2000. Inhibition of the ecto-ATP diphosphohydrolase of
648 *Schistosoma mansoni* by thapsigargin. *Biosci Rep* 20:369-381.

649 Morris GP, and Threadgold LT. 1968. Ultrastructure of the tegument of adult *Schistosoma mansoni*. *J*
650 *Parasitol* 54:15-27.

651 Ndegwa D, Krautz-Peterson G, and Skelly PJ. 2007. Protocols for gene silencing in schistosomes. *Exp*
652 *Parasitol* 117:284-291.

653 Pellegrino J, and Coelho PM. 1978. *Schistosoma mansoni*: wandering capacity of a worm couple. *J*
654 *Parasitol* 64:181-182.

655 Pujol FH, Liprandi F, Rodriguez M, and Cesari IM. 1990. Production of a mouse monoclonal antibody
656 against the alkaline phosphatase of adult *Schistosoma mansoni*. *Mol Biochem Parasitol* 40:43-52.

657 Punj V, Zaborina O, Dhiman N, Falzari K, Bagdasarian M, and Chakrabarty AM. 2000. Phagocytic cell
658 killing mediated by secreted cytotoxic factors of *Vibrio cholerae*. *Infection and immunity* 68:4930-4937.

659 Riches DW, Watkins JL, Henson PM, and Stanworth DR. 1985. Regulation of macrophage lysosomal
660 secretion by adenosine, adenosine phosphate esters, and related structural analogues of adenosine. *J Leukoc*
661 *Biol* 37:545-557.

662 Rofatto HK, Araujo-Montoya BO, Miyasato PA, Levano-Garcia J, Rodriguez D, Nakano E, Verjovski-
663 Almeida S, Farias LP, and Leite LC. 2013. Immunization with tegument nucleotidases associated with a
664 subcurative praziquantel treatment reduces worm burden following *Schistosoma mansoni* challenge. *PeerJ*
665 1:e58.

666 Rofatto HK, Tararam CA, Borges WC, Wilson RA, Leite LC, and Farias LP. 2009. Characterization of
667 phosphodiesterase-5 as a surface protein in the tegument of *Schistosoma mansoni*. *Mol Biochem Parasitol*
668 166:32-41.

669 Rogers TB, Inesi G, Wade R, and Lederer WJ. 1995. Use of thapsigargin to study Ca²⁺ homeostasis in
670 cardiac cells. *Biosci Rep* 15:341-349.

671 Senft AW, Philpott DE, and Pelofsky AH. 1961. Electron microscopy of the integument, flame cells, and
672 gut of *Schistosoma mansoni*. *J Parasitol* 47:217-229.

673 Silk MH, Spence IM, and Gear JH. 1969. Ultrastructural studies of the blood fluke--*Schistosoma mansoni*.
674 I. The integument. *S Afr J Med Sci* 34:1-10.

675 Skelly PJ, Da'dara A, and Harn DA. 2003. Suppression of cathepsin B expression in *Schistosoma mansoni*
676 by RNA interference. *Int J Parasitol* 33:363-369.

677 Smith JH, and von Lichtenberg F. 1974. Observations on the ultrastructure of the tegument of *Schistosoma*
678 *mansoni* in mesenteric veins. *Am J Trop Med Hyg* 23:71-77.

679 Thammavongsa V, Kern JW, Missiakas DM, and Schneewind O. 2009. *Staphylococcus aureus* synthesizes
680 adenosine to escape host immune responses. *J Exp Med* 206:2417-2427.

681 Torres CR, Vasconcelos EG, Ferreira ST, and Verjovski-Almeida S. 1998. Divalent cation dependence and
682 inhibition of *Schistosoma mansoni* ATP diphosphohydrolase by fluorosulfonylbenzoyl adenosine. *Eur J*
683 *Biochem* 251:516-521.

684 van Balkom BW, van Gestel RA, Brouwers JF, Krijgsveld J, Tielens AG, Heck AJ, and van Hellemond JJ.
685 2005. Mass spectrometric analysis of the Schistosoma mansoni tegumental sub-proteome. *J Proteome Res*
686 4:958-966.

687 Vasconcelos EG, Ferreira ST, Carvalho TM, Souza W, Kettlun AM, Mancilla M, Valenzuela MA, and
688 Verjovski-Almeida S. 1996. Partial purification and immunohistochemical localization of ATP
689 diphosphohydrolase from Schistosoma mansoni. Immunological cross-reactivities with potato apyrase and
690 Toxoplasma gondii nucleoside triphosphate hydrolase. *J Biol Chem* 271:22139-22145.

691 Vasconcelos EG, Nascimento PS, Meirelles MN, Verjovski-Almeida S, and Ferreira ST. 1993.
692 Characterization and localization of an ATP-diphosphohydrolase on the external surface of the tegument of
693 Schistosoma mansoni. *Mol Biochem Parasitol* 58:205-214.

694 Vennervald BJ, and Dunne DW. 2004. Morbidity in schistosomiasis: an update. *Curr Opin Infect Dis*
695 17:439-447.

696 Vivian JP, Riedmaier P, Ge H, Le Nours J, Sansom FM, Wilce MC, Byres E, Dias M, Schmidberger JW,
697 Cowan PJ et al. . 2010. Crystal structure of a Legionella pneumophila ecto -triphosphate
698 diphosphohydrolase, a structural and functional homolog of the eukaryotic NTPDases. *Structure* 18:228-
699 238.

700 Yegutkin GG. 2008. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of
701 purinergic signalling cascade. *Biochim Biophys Acta* 1783:673-694.

702 Zaborina O, Li X, Cheng G, Kapatral V, and Chakrabarty AM. 1999. Secretion of ATP-utilizing enzymes,
703 nucleoside diphosphate kinase and ATPase, by Mycobacterium bovis BCG: sequestration of ATP from
704 macrophage P2Z receptors? *Mol Microbiol* 31:1333-1343.

705
706

Figure 1.

Ecto-nucleotidase activity in schistosomes.

A, Phosphate (nmol) release following the addition of ATP, ADP or AMP (2mM) to individual live adult male worms over 3 hours. B, Phosphate (nmol) release following the addition of ATP, ADP or AMP (2mM) to 1,000 schistosomula over 1 hour. C, The proposed pathway in schistosomes for exogenous ATP catabolism via ADP and AMP to adenosine. The following three schistosome tegumental ectoenzymes are hypothesized to be involved: SmAP (*S. mansoni* alkaline phosphatase), SmNPP-5 (*S. mansoni* nucleotide pyrophosphatase-phosphodiesterase-5) and SmATPDase1 (*S. mansoni* ATP diphosphohydrolase1).




Figure 2.

Suppression of schistosome ectoenzyme genes using RNAi.

SmAP (A), Sm NPP-5 (B) and SmATPDase1 (C) gene expression in schistosomula treated with SmAP, SmNPP-5, SmATPDase1 (SmATPD), control (grey bar) or no (None) siRNA. One group was treated with siRNAs simultaneously targeting the three ectoenzyme genes (SmAP and SmNPP-5 and SmATPDase1, lane marked “All 3”). In all cases target gene suppression is significantly different from control ($P<0.05$). D, Western blotting analysis in which protein extracts of parasites treated either with siRNAs simultaneously targeting the three ectoenzyme genes (SmAP and SmNPP-5 and SmATPDase1, lane marked “All 3”) or control siRNA or no siRNA (None) are probed with antibody specific for SmAP (top panel), or SmNPP-5 (second panel), or SmATPDase1 (third panel). The bottom panel shows a fragment of the gel stained with Coomassie blue to ensure roughly equal protein loading per lane.




Figure 3.

Apyrase activity of ecto-enzyme suppressed and control parasites.

Enzyme activity (phosphate (Pi) release per hour, mean \pm SE) from individual, living adult male schistosomes (≥ 8 /group) treated with the indicated siRNAs and incubated with 2mM ATP (A) or ADP (B). In both cases, significantly lower activity is seen in parasites treated with siRNA targeting SmATPDase1 (grey bars) compared to all other groups ($P < 0.05$).




Figure 4.

Expression of recombinant SmATPDase1.

A. Depiction of the full length 544 amino acid SmATPDase1 protein (top) which contains two transmembrane (TM) domains. Numbers refer to amino acid residues. A truncated version of the protein from residues S⁶⁶ to Q⁵⁰⁷, lacking both TM domains, and predicted to be secreted following expression in CHO cells is depicted below. B. ATPase activity in CHO-S cell lysates (10 μ g/assay) three days after transfection with a full length or secreted or no (None) DNA construct. The inset shows ATPase activity on the surface of living CHO-S cells (75 x10³ or 150 x10³) three days after transfection with a full length or no (control) DNA construct. C. ADPase activity in CHO-S cell lysates (10 μ g/assay) three days after transfection with a full length or secreted or no (None) DNA construct. The inset shows ADPase activity on the surface of living CHO-S cells (75 x10³ or 150 x10³) three days after transfection with a full length or no (control) DNA construct. In all cases only the activity of the full length construct differs significantly from other groups ($P < 0.05$).




Figure 5.

Characterization of recombinant SmATPDase1.

The top panel (A-C) deals with ATP and the lower panel (D-F) deals with ADP. ATPase activity (A) and ADPase activity (D) in cell lysates expressing SmATPDase1 (10 μg protein) in the presence of added calcium (Ca^{++}) or magnesium (Mg^{++}) or nothing (None) or EDTA plus EGTA or Ca^{++} plus thapsigargin (100 μM). Michaelis-Menton plot of ATPase activity (B) and ADPase activity (E) in cell lysates expressing rSmATPDase1. The K_m for ATP is 0.4 ± 0.02 mM and the K_m for ADP is 0.252 ± 0.02 mM. The effect of pH on ATPase activity (C) and ADPase activity (F) in cell lysates expressing SmATPDase1.




Figure 6.

The pathway in schistosomes for exogenous ATP catabolism via ADP and AMP to adenosine.

Work reported here demonstrates that, of the three ectoenzyme candidates, only SmATPDase1 (*S. mansoni* ATP diphosphohydrolase1) can cleave ATP and ADP. In the final step, SmAP (*S. mansoni* alkaline phosphatase) can cleave AMP to generate adenosine.




Table 1.

Sequences of oligonucleotides used in qRT-PCR analysis.

For each gene a forward (F) and reverse (R) primer were used in conjunction with a FAM dye labeled probe.

Gene	Primer name	Sequence
SmAP	SmAP-F	5'-GCCATCCGACAAGGAATATAAGTGT -3'
	Sm-AP-R	5'-GGTCCATTGAAAAAGGAGGATATGAGA -3'
	Sm-AP-FAM	5'- FAM - ATCTCCTTTTGCAGTATTATC -3'
SmNPP-5	SmNPP-5-F	5'-GGACGATTATTGCTGACAGAACGT -3'
	SmNPP-5-R	5'-TGGAGACATCTCTTTGTAATCTGGATCA -3'
	SmNPP-FAM	5'- FAM -TTTATTTTTCAGGGTTATCCC -3'
SmATPDase1	SmATPd-F	5'-CTGATGCCGTTATGAAGTTTTGCA -3'
	SmATPd-R	5'-ACCTTCAGCAAGTGCATGTTGA-3'
	SmATPd-FAM	5'- FAM - AAAGATGTGGCTAAAATT -3'
α-Tubulin	Tub-F	5'-GGTTGACAACGAGGCCATTTATG-3'
	Tub-R	5'-GCAGTAAACCCTTGGTCAGATAATTTTG -3'
	Tub-Probe	5'- FAM -ATATTTGTCGACGGAAT-3'